Why the 2026 update matters to public‑health organisations

EU4Health is the European Union’s flagship health programme for the 2021‑2027 period. In its second half, the programme introduces a revised set of Surveillance Grants designed to strengthen cross‑border monitoring of infectious diseases, environmental hazards, and health‑related data gaps. For national agencies, research institutes, and NGOs that rely on EU funding, the 2026 changes affect eligibility, budgeting, reporting, and the way projects are evaluated.

Understanding the new rules helps applicants avoid costly re‑designs, align their work with EU priorities, and increase the likelihood of receiving a grant. The sections below walk through the key modifications, compare the old and new frameworks, and explain the practical steps you need to take before the next call for proposals.

What the 2026 Surveillance Grants cover

Surveillance Grants under EU4Health aim to generate timely, high‑quality data that can inform policy and emergency response. In 2026 the scope is divided into three thematic pillars:

Infectious disease monitoring – includes early‑warning systems for zoonoses, antimicrobial resistance (AMR) trends, and pandemic‑preparedness platforms.
Environmental and chemical health surveillance – focuses on air‑quality networks, water‑borne pathogen tracking, and exposure to emerging contaminants.
Health‑system performance data – covers metrics on hospital capacity, workforce shortages, and health‑technology assessment outcomes.

Each pillar now requires a minimum of one “cross‑border data‑exchange component.” Projects that rely solely on national data streams are considered incomplete unless they demonstrably feed into an EU‑wide repository.

Eligibility shifts: Who can apply?

The 2026 revision narrows the field of eligible applicants while expanding the definition of “partner.” The main changes are:

Aspect	Before 2026	After 2026
Primary applicant	Any public authority, university, or non‑profit in an EU Member State.	Must be a recognised “public‑health institution” (e.g., national health agency, regional health authority, or accredited research centre).
Co‑applicants	Allowed but not required.	At least two additional partners from different Member States are mandatory.
Private sector	Can participate as a co‑partner.	Limited to “service‑provider” role; cannot be a lead applicant.
Non‑EU entities	Associate‑country participation possible.	Only as “observer” partners without voting rights on budgets.

These adjustments aim to foster genuine transnational collaboration and reduce the risk of duplicated surveillance efforts.

Budgetary limits and funding structure

The total ceiling for a single Surveillance Grant rises from €10 million to €15 million, reflecting the increased data‑infrastructure requirements. However, the EU caps the “direct research cost” portion at 70 % of the overall budget, up from 60 %. The remaining 30 % must be allocated to:

Data‑harmonisation activities (e.g., standardising case definitions).
Cross‑border coordination meetings and joint training sessions.
Open‑access data‑platform maintenance for the duration of the grant.

Applicants also need to submit a “cost‑sharing” declaration. The minimum co‑financing ratio stays at 20 % of total eligible costs, but member‑state contributions can now be counted as in‑kind support if they involve existing surveillance infrastructure.

Key procedural changes in the application cycle

The application timeline remains roughly the same—a call in March, proposal deadline in June, and grant award in September—but the procedural steps have been refined:

1. Pre‑proposal self‑assessment tool

Before submitting a full proposal, applicants must complete an online self‑assessment. The tool checks alignment with the three thematic pillars, verifies the presence of at least two cross‑border partners, and flags any budget items that exceed the new 70 % research‑cost limit. Failure to pass the self‑assessment halts the process, saving time for both applicants and evaluators.

2. Mandatory data‑governance plan

All proposals must attach a 5‑page data‑governance plan describing:

Legal basis for data sharing (GDPR compliance, data‑processing agreements).
Metadata standards to be used (e.g., ISO 27799, HL7 FHIR).
Data‑access policy for third‑party researchers after the project ends.

This requirement replaces the previous “ethical considerations” narrative, putting concrete data‑management actions at the forefront.

3. Two‑stage evaluation

First, a “technical review” assesses feasibility, data‑quality methodology, and cross‑border relevance. Second, a “strategic review” evaluates the alignment with EU health priorities, especially the “One Health” approach that links human, animal, and environmental health. Scores from both stages are combined, and only proposals scoring above 65 % move to the funding decision.

How the reporting format has been simplified

Earlier grants required quarterly narrative reports and a separate financial statement. Starting in 2026, grantees will use a unified “EU‑Health Dashboard” that automatically pulls financial data from the grant management system and merges it with key performance indicators (KPIs) entered by the project team.

The dashboard includes mandatory fields for:

Number of new surveillance sites activated.
Volume of data points uploaded to the EU‑wide repository.
Time between data collection and public release (target ≤ 48 hours for infectious disease alerts).

Filling out the dashboard is required every three months; a final comprehensive report replaces the previous “end‑of‑project narrative.”

Impact on existing projects

Projects that received a grant under the 2021‑2025 rules are not automatically discontinued. However, they must submit a “transition plan” by 31 December 2025 to align with the new cross‑border data‑exchange requirement. Failure to submit the plan results in a reduction of up to 20 % of the remaining budget.

Transition plans typically involve:

Mapping current data flows to the EU‑wide platform specifications.
Negotiating data‑sharing agreements with at least one partner in another Member State.
Re‑allocating a portion of the budget to meet the new 30 % non‑research cost requirement.

Projects that successfully adapt can continue receiving full funding and may become eligible for additional “extension grants” that support the integration work.

Practical steps to prepare for the 2026 call

Below is a checklist that aligns with the new requirements. Follow it well before the March call opens.

Identify cross‑border partners early. Reach out to at least two institutions in different Member States and draft a memorandum of understanding (MoU) that outlines data‑sharing responsibilities.
Map your data‑infrastructure. Ensure you can produce data in ISO 27799 or HL7 FHIR format. If not, budget for a short‑term conversion tool.
Run the pre‑proposal self‑assessment. The online tool is available from November 2025. Use the feedback to adjust scope or budget before the formal deadline.
Develop a data‑governance plan. Include a GDPR impact assessment and a clear data‑access policy for post‑project use.
Align budget categories. Verify that research costs do not exceed 70 % of total eligible expenses. Allocate the remaining 30 % to coordination, platform maintenance, and training.
Plan for the EU‑Health Dashboard. Assign a staff member to be responsible for quarterly KPI entry and ensure they are trained on the dashboard interface.
Prepare a transition strategy (if you have an existing grant). Draft a timeline for integrating your data with the EU‑wide repository and submit the plan by the end of 2025.

Common pitfalls and how to avoid them

Even experienced applicants have stumbled over the new rules. The most frequent errors are:

Missing the cross‑border partner requirement. Some proposals list a partner from an associated country but not a full EU Member State, which is insufficient.
Exceeding the research‑cost ceiling. Budgets that heavily weight laboratory analyses without corresponding coordination costs are flagged during the self‑assessment.
Inadequate data‑governance documentation. Submitting a generic ethics statement instead of a detailed plan leads to automatic rejection.
Late submission of the transition plan. Existing grantees who wait until the last month often miss the 31 December deadline, triggering budget cuts.

Address each item early in the drafting stage. A peer review by a partner institution can catch oversights before the formal submission.

How the changes support the EU’s broader health goals

The 2026 revisions are not isolated tweaks; they fit within the EU’s “Health‑in‑All‑Policies” agenda and the “One Health” strategy. By mandating cross‑border data exchange, the programme seeks to:

Reduce duplicate surveillance efforts across Member States.
Accelerate detection of transnational health threats.
Provide policymakers with comparable, high‑quality evidence for rapid decision‑making.
Strengthen the EU’s capacity to meet International Health Regulations (IHR) reporting obligations.

In practice, this means that a surveillance network for West Nile virus that spans Spain, Italy, and Greece will now be able to share case data in near real‑time, allowing health ministries to coordinate vector‑control measures more efficiently.

Looking ahead: Potential future adjustments

While the 2026 rules are the latest major update, the EU Commission reviews EU4Health annually. Anticipated areas for future refinement include:

Greater emphasis on digital health‑surveillance tools, such as AI‑driven outbreak prediction.
Possible expansion of the “environmental health” pillar to cover microplastics monitoring.
Introduction of a “rapid‑response add‑on” that can be triggered for emergent crises without a new call.

Stakeholders are encouraged to follow the EU Health Programme website and participate in public consultations, which are scheduled for late 2026.

EU4Health Surveillance Grants: What’s Changing in 2026